Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis

Gloris Sánchez, Julio S. Castro, Soham Al Snih al snih, Luísa Pérez Blanco, María H. Esteva, Ernesto García MacGregor, Marielena González, Ysabel Granados, Francisco Marín, Alexis Rosas, Antonio Tristano, Esther Chirinos, Luís Mundaraín, Gilberto Sanoja, Guisela Zambrano-Marín, Martín A. Rodríguez

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A multicenter, national, retrospective, and cross-sectional study of 219 hospital-based Venezuelan patients with rheumatoid arthritis (RA) was aimed to evaluate the probability of continuity of treatment with oral methotrexate (MTX). Treatment survival decreased from 92% at 12 months to 42% at 180 months, as assessed by life table analysis and the Kaplan-Meier method. Forty-seven patients stopped treatment and adverse effects (29.7%) and lack of continuous access to medication (19.1%) were the most common causes for withdrawal. MTX survival was decreased in the group with combined MTX plus leflunomide therapy, as shown by the log-rank test. Venezuelan patients with RA have a probability of continuing treatment with oral MTX comparable to non-Hispanic patient populations. However, concomitant use of leflunomide may increase the risk of interruption of MTX treatment in this RA population.

Original languageEnglish (US)
Pages (from-to)531-536
Number of pages6
JournalRheumatology International
Volume27
Issue number6
DOIs
StatePublished - Apr 2007

Fingerprint

Methotrexate
Rheumatoid Arthritis
leflunomide
Therapeutics
Life Tables
Survival
Population
Cross-Sectional Studies

Keywords

  • Latin America
  • Methotrexate
  • Rheumatoid arthritis
  • Tolerability

ASJC Scopus subject areas

  • Rheumatology

Cite this

Sánchez, G., Castro, J. S., Al Snih al snih, S., Blanco, L. P., Esteva, M. H., MacGregor, E. G., ... Rodríguez, M. A. (2007). Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis. Rheumatology International, 27(6), 531-536. https://doi.org/10.1007/s00296-006-0261-x

Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis. / Sánchez, Gloris; Castro, Julio S.; Al Snih al snih, Soham; Blanco, Luísa Pérez; Esteva, María H.; MacGregor, Ernesto García; González, Marielena; Granados, Ysabel; Marín, Francisco; Rosas, Alexis; Tristano, Antonio; Chirinos, Esther; Mundaraín, Luís; Sanoja, Gilberto; Zambrano-Marín, Guisela; Rodríguez, Martín A.

In: Rheumatology International, Vol. 27, No. 6, 04.2007, p. 531-536.

Research output: Contribution to journalArticle

Sánchez, G, Castro, JS, Al Snih al snih, S, Blanco, LP, Esteva, MH, MacGregor, EG, González, M, Granados, Y, Marín, F, Rosas, A, Tristano, A, Chirinos, E, Mundaraín, L, Sanoja, G, Zambrano-Marín, G & Rodríguez, MA 2007, 'Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis', Rheumatology International, vol. 27, no. 6, pp. 531-536. https://doi.org/10.1007/s00296-006-0261-x
Sánchez, Gloris ; Castro, Julio S. ; Al Snih al snih, Soham ; Blanco, Luísa Pérez ; Esteva, María H. ; MacGregor, Ernesto García ; González, Marielena ; Granados, Ysabel ; Marín, Francisco ; Rosas, Alexis ; Tristano, Antonio ; Chirinos, Esther ; Mundaraín, Luís ; Sanoja, Gilberto ; Zambrano-Marín, Guisela ; Rodríguez, Martín A. / Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis. In: Rheumatology International. 2007 ; Vol. 27, No. 6. pp. 531-536.
@article{169e02c593f84cc8be43eca63871226f,
title = "Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis",
abstract = "A multicenter, national, retrospective, and cross-sectional study of 219 hospital-based Venezuelan patients with rheumatoid arthritis (RA) was aimed to evaluate the probability of continuity of treatment with oral methotrexate (MTX). Treatment survival decreased from 92{\%} at 12 months to 42{\%} at 180 months, as assessed by life table analysis and the Kaplan-Meier method. Forty-seven patients stopped treatment and adverse effects (29.7{\%}) and lack of continuous access to medication (19.1{\%}) were the most common causes for withdrawal. MTX survival was decreased in the group with combined MTX plus leflunomide therapy, as shown by the log-rank test. Venezuelan patients with RA have a probability of continuing treatment with oral MTX comparable to non-Hispanic patient populations. However, concomitant use of leflunomide may increase the risk of interruption of MTX treatment in this RA population.",
keywords = "Latin America, Methotrexate, Rheumatoid arthritis, Tolerability",
author = "Gloris S{\'a}nchez and Castro, {Julio S.} and {Al Snih al snih}, Soham and Blanco, {Lu{\'i}sa P{\'e}rez} and Esteva, {Mar{\'i}a H.} and MacGregor, {Ernesto Garc{\'i}a} and Marielena Gonz{\'a}lez and Ysabel Granados and Francisco Mar{\'i}n and Alexis Rosas and Antonio Tristano and Esther Chirinos and Lu{\'i}s Mundara{\'i}n and Gilberto Sanoja and Guisela Zambrano-Mar{\'i}n and Rodr{\'i}guez, {Mart{\'i}n A.}",
year = "2007",
month = "4",
doi = "10.1007/s00296-006-0261-x",
language = "English (US)",
volume = "27",
pages = "531--536",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis

AU - Sánchez, Gloris

AU - Castro, Julio S.

AU - Al Snih al snih, Soham

AU - Blanco, Luísa Pérez

AU - Esteva, María H.

AU - MacGregor, Ernesto García

AU - González, Marielena

AU - Granados, Ysabel

AU - Marín, Francisco

AU - Rosas, Alexis

AU - Tristano, Antonio

AU - Chirinos, Esther

AU - Mundaraín, Luís

AU - Sanoja, Gilberto

AU - Zambrano-Marín, Guisela

AU - Rodríguez, Martín A.

PY - 2007/4

Y1 - 2007/4

N2 - A multicenter, national, retrospective, and cross-sectional study of 219 hospital-based Venezuelan patients with rheumatoid arthritis (RA) was aimed to evaluate the probability of continuity of treatment with oral methotrexate (MTX). Treatment survival decreased from 92% at 12 months to 42% at 180 months, as assessed by life table analysis and the Kaplan-Meier method. Forty-seven patients stopped treatment and adverse effects (29.7%) and lack of continuous access to medication (19.1%) were the most common causes for withdrawal. MTX survival was decreased in the group with combined MTX plus leflunomide therapy, as shown by the log-rank test. Venezuelan patients with RA have a probability of continuing treatment with oral MTX comparable to non-Hispanic patient populations. However, concomitant use of leflunomide may increase the risk of interruption of MTX treatment in this RA population.

AB - A multicenter, national, retrospective, and cross-sectional study of 219 hospital-based Venezuelan patients with rheumatoid arthritis (RA) was aimed to evaluate the probability of continuity of treatment with oral methotrexate (MTX). Treatment survival decreased from 92% at 12 months to 42% at 180 months, as assessed by life table analysis and the Kaplan-Meier method. Forty-seven patients stopped treatment and adverse effects (29.7%) and lack of continuous access to medication (19.1%) were the most common causes for withdrawal. MTX survival was decreased in the group with combined MTX plus leflunomide therapy, as shown by the log-rank test. Venezuelan patients with RA have a probability of continuing treatment with oral MTX comparable to non-Hispanic patient populations. However, concomitant use of leflunomide may increase the risk of interruption of MTX treatment in this RA population.

KW - Latin America

KW - Methotrexate

KW - Rheumatoid arthritis

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=33947145285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947145285&partnerID=8YFLogxK

U2 - 10.1007/s00296-006-0261-x

DO - 10.1007/s00296-006-0261-x

M3 - Article

C2 - 17102944

AN - SCOPUS:33947145285

VL - 27

SP - 531

EP - 536

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 6

ER -